305 related articles for article (PubMed ID: 26011312)
1. Expression analysis of microRNA-125 in patients with polycythemia vera and essential thrombocythemia and correlation with JAK2 allele burden and laboratory findings.
Ferdowsi S; Atarodi K; Amirizadeh N; Toogeh G; Azarkeivan A; Shirkoohi R; Faranoush M; Vaezi M; Alimoghaddam K; Ghavamzadeh A; Naghadeh HT; Ghaffari SH
Int J Lab Hematol; 2015 Oct; 37(5):661-7. PubMed ID: 26011312
[TBL] [Abstract][Full Text] [Related]
2. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
3. Role of JAK2 V617F mutation and aberrant expression of microRNA-143 in myeloproliferative neoplasms.
Benati M; Montagnana M; Danese E; De Matteis G; Veneri D; Paviati E; Guidi GC
Clin Chem Lab Med; 2015 Jun; 53(7):1005-11. PubMed ID: 25527813
[TBL] [Abstract][Full Text] [Related]
4. Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET).
Zhao S; Zhang X; Xu Y; Feng Y; Sheng W; Cen J; Wu D; Han Y
Int J Med Sci; 2016; 13(1):85-91. PubMed ID: 26917989
[TBL] [Abstract][Full Text] [Related]
5. JAK2V617F allele burden in patients with myeloproliferative neoplasms.
Alshemmari SH; Rajaan R; Ameen R; Al-Drees MA; Almosailleakh MR
Ann Hematol; 2014 May; 93(5):791-6. PubMed ID: 24362471
[TBL] [Abstract][Full Text] [Related]
6. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
7. [Correlation of JAK2V617F mutation burden with clinical features in patients with polycythemia vera and essential thrombocythemia].
Liu HX; Tong CR; Cai P; Teng W; Wang H; Zhang Y; Zhu P
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):742-5. PubMed ID: 19549399
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA expression and JAK2 allele burden in bone marrow trephine biopsies of polycythemia vera, essential thrombocythemia and early primary myelofibrosis.
Gebauer N; Bernard V; Gebauer W; Feller AC; Merz H
Acta Haematol; 2013; 129(4):251-6. PubMed ID: 23343777
[TBL] [Abstract][Full Text] [Related]
9. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
10. Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients.
Besses C; Alvarez-Larrán A; Martínez-Avilés L; Mojal S; Longarón R; Salar A; Florensa L; Serrano S; Bellosillo B
Br J Haematol; 2011 Feb; 152(4):413-9. PubMed ID: 21219298
[TBL] [Abstract][Full Text] [Related]
11. The role of serum erythropoietin level and JAK2 V617F allele burden in the diagnosis of polycythaemia vera.
Ancochea A; Alvarez-Larrán A; Morales-Indiano C; García-Pallarols F; Martínez-Avilés L; Angona A; Senín A; Bellosillo B; Besses C
Br J Haematol; 2014 Nov; 167(3):411-7. PubMed ID: 25040297
[TBL] [Abstract][Full Text] [Related]
12. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera.
Lippert E; Boissinot M; Kralovics R; Girodon F; Dobo I; Praloran V; Boiret-Dupré N; Skoda RC; Hermouet S
Blood; 2006 Sep; 108(6):1865-7. PubMed ID: 16728702
[TBL] [Abstract][Full Text] [Related]
13. Quantitative assessment of the JAK2 V617F allele burden: equivalent levels in peripheral blood and bone marrow.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Leukemia; 2008 Jan; 22(1):194-5. PubMed ID: 17625603
[No Abstract] [Full Text] [Related]
14. Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera.
Ganly P; Hanrahan V; Baker B; Romeril K
Am J Hematol; 2007 Jan; 82(1):80-2. PubMed ID: 16924638
[TBL] [Abstract][Full Text] [Related]
15. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
[TBL] [Abstract][Full Text] [Related]
16. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
[TBL] [Abstract][Full Text] [Related]
17. Influence of JAK2 46/1 haplotype in the natural evolution of JAK2V617F allele burden in patients with myeloproliferative neoplasms.
Alvarez-Larrán A; Angona A; Martínez-Avilés L; Bellosillo B; Besses C
Leuk Res; 2012 Mar; 36(3):324-6. PubMed ID: 22001278
[TBL] [Abstract][Full Text] [Related]
18.
Sassi H; Menif S; Ammar SB; Farrah A; Othmen HBH; Amouri H
Pan Afr Med J; 2021; 39():194. PubMed ID: 34603575
[TBL] [Abstract][Full Text] [Related]
19. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
[TBL] [Abstract][Full Text] [Related]
20. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]